UBS Group
BOLD

UBS Group’s Audentes Therapeutics, Inc BOLD Stock Holding History

UBS Group’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-752,003
Closed -$45M – 8859
2019
Q4 		$45M Buy
752,003
+650,385
+640% +$24.4M 0.02% 837
2019
Q3 		$2.85M Buy
101,618
+66,938
+193% +$2.28M ﹤0.01% 2938
2019
Q2 		$1.31M Buy
34,680
+6,180
+22% +$237K ﹤0.01% 3521
2019
Q1 		$1.11M Sell
28,500
-98,990
-78% -$2.84M ﹤0.01% 3497
2018
Q4 		$2.72M Buy
127,490
+118,660
+1,344% +$3.06M ﹤0.01% 2721
2018
Q3 		$350K Sell
8,830
-678
-7% -$25.3K ﹤0.01% 4654
2018
Q2 		$364K Sell
9,508
-41,024
-81% -$1.52M ﹤0.01% 4553
2018
Q1 		$1.52M Buy
50,532
+41,696
+472% +$1.41M ﹤0.01% 3351
2017
Q4 		$276K Buy
8,836
+1,020
+13% +$28K ﹤0.01% 4696
2017
Q3 		$219K Buy
7,816
+7,219
+1,209% +$157K ﹤0.01% 4782
2017
Q2 		$11K Buy
597
+580
+3,412% +$9.27K ﹤0.01% 6743
2017
Q1 		$0 Buy
+17
New +$275 ﹤0.01% 8186
2016
Q4 		– Sell
-1,394
Closed -$25K – 8202
2016
Q3 		$25K Buy
+1,394
New +$21.2K ﹤0.01% 6117

UBS Group's BOLD Position: Q1 2020 in Review

UBS Group sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 752,003 shares — an estimated $45M sold.

UBS Group first reported a position in BOLD in Q3 2016 and held it in 13 quarters. The position peaked at $45M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

  • UBS Group reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • UBS Group sold 752,003 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $45M.
  • UBS Group first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 13 quarters.
  • UBS Group's Audentes Therapeutics, Inc position peaked at $45M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.